The deal between Jiangning Development Zone-based Help Therapeutics and China Resources paves the way for a major rollout of its revolutionary HiCM-188 which meets the unmet need for severe heart failure currently undergoing clinical trials. Full story (in Chinese) via this link; read about Nanjing introduced as never before via this link.